Lotus Bio-Technology Development Corp. said its normalized net income for the fiscal third quarter ended Dec. 31, 2015, amounted to a loss of $4,080, compared with a loss of $8,100 in the year-earlier period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
Reported net income came to a loss of $6,530, or a loss of 0 cents per share, compared to a loss of $12,960, or a loss of 0 cents per share, in the year-earlier period.
